[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gout-arthritis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gout-arthritis":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,53,79,103,132,166],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":4},"100621361","phase-4-hla-b5801-guided-therapy-for-gout-effectiveness-safety-and-cost-effectiveness-100621361",false,"NCT07369622","HLA-B*58:01-Guided Therapy for Gout: Effectiveness, Safety, and Cost-Effectiveness","A Prospective Interventional Study Comparing Genotype-Guided Therapy Versus Usual Care to Prevent Severe Cutaneous Adverse Reactions Associated With Allopurinol and Carbamazepine in Vietnam","HLA-SCREEN","Inclusion Criteria:\n\n* Age ≥ 18 years.\n\nDiagnosis of gout according to the 2020 ACR\u002FEULAR classification criteria.\n\nIndicated for initiation of urate-lowering therapy (ULT) and allopurinol-naïve (no prior allopurinol exposure).\n\nAble and willing to comply with scheduled follow-up visits (baseline, Months 1, 3, 6, and 12).\n\nProvides written informed consent for participation.\n\nFor the genotyping arms: provides consent for blood sampling and HLA-B\\*58:01 genotyping.\n\nExclusion Criteria:\n\n* Prior use of allopurinol or history of hypersensitivity reaction to allopurinol.\n\nKnown hypersensitivity to febuxostat (for participants who would receive febuxostat).\n\nCurrent or recent severe skin reaction (suspected\u002Fconfirmed SCAR) from any cause.\n\nEnd-stage kidney disease requiring dialysis or kidney transplantation.\n\nSevere hepatic impairment or active severe liver disease (e.g., AST\u002FALT \\>3× ULN at baseline).\n\nSevere uncontrolled medical conditions that, in the investigator's judgment, could interfere with treatment or follow-up (e.g., decompensated heart failure, active malignancy requiring intensive treatment).\n\nUse of systemic immunosuppressive therapy (e.g., high-dose corticosteroids, biologics, chemotherapy) at enrollment.\n\nPregnancy or breastfeeding.\n\nParticipation in another interventional clinical study that could affect the outcomes of this study.\n\nInability to provide informed consent or inability to adhere to study procedures.",true,"ALL",{"count":20,"type":21},228,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","Severe cutaneous adverse reactions (SCARs), such as Stevens-Johnson syndrome\u002Ftoxic epidermal necrolysis (SJS\u002FTEN) and drug reaction with eosinophilia and systemic symptoms (DRESS), are rare but life-threatening complications that can occur after starting allopurinol for gout. The HLA-B58:01 allele is a strong genetic risk factor for allopurinol-associated SCARs in Asian populations. This study evaluates the feasibility and clinical value of HLA-B58:01 screening before first-time allopurinol use in Vietnamese adults with gout.\n\nAdults (≥18 years) diagnosed with gout (ACR\u002FEULAR 2020 criteria) and initiating urate-lowering therapy will be enrolled at Hai Phong International General Hospital (January 2025-June 2027). Participants who undergo HLA-B58:01 genotyping (PCR-based assay) will be treated according to test results: HLA-B58:01 negative participants receive allopurinol; HLA-B58:01 positive participants receive febuxostat. A comparison group consists of patients treated with febuxostat without HLA testing. Participants will be followed for 12 months with assessments at baseline, 1, 3, 6, and 12 months to monitor serum uric acid, gout flares, and safety outcomes (SCARs and other adverse events, including liver and kidney function). The study also includes an economic evaluation to estimate the cost-effectiveness of HLA-B58:01 screening for preventing SCARs and optimizing gout treatment.",[27,28,29],"Gout Initiating Urate-loweringUrate-lowering Therapy","Gout Arthritis","Gout and Hyperuricemia",[31,32,33,34,35,36,37,38,39,40],"HLA-B*58:01","HLA genotyping","Pharmacogenomics","Allopurinol","febuxostat","Pharmacogenetic screening","Severe cutaneous adverse reactions (SCARs)","Stevens-Johnson syndrome (SJS)","Toxic epidermal necrolysis (TEN)","Cost-effectiveness analysis","NOT_YET_RECRUITING","2026-01-18",{"date":44,"type":45},"2026-01-27","ACTUAL",{"date":47,"type":21},"2026-01-20",{"date":49,"type":21},"2028-12-30",{"name":51,"class":52},"Haiphong University of Medicine and Pharmacy","OTHER",{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":18,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":4,"studyType":22,"phases":64,"briefSummary":65,"conditions":66,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":78},"100619550","phase-4-purified-cortrophin-gel-efficacy-and-safety-study-of-2-dose-levels-in-patients-with-acute-gout-flares-100619550","NCT07346079","Purified Cortrophin® Gel Efficacy and Safety Study of 2 Dose Levels in Patients With Acute Gout Flares","A Randomized, Multicenter, Double-blind, Efficacy and Safety Study of 2 Dose Levels of Purified Cortrophin® Gel in Patients With Acute Gouty Arthritis Flares","Inclusion Criteria:\n\n* Signed informed consent to participate in this study\n* Male and female patients, aged 18-85 years\n* Meeting the 2015 Gout classification criteria of the ACR\u002FEULAR collaborative initiative\n* Onset of current acute gout flare within 5 days prior to study entry\n* Body mass index of less than or equal to 45 kg\u002Fm2\n* Baseline pain intensity ≥ 50 mm on the 0-100 mm visual analog scale (VAS)\n* History of ≥ 1 gout flares within the 12 months prior to study entry\n* The patient meets at least one of the following criteria for both NSAIDs and colchicine treatment options:\n* Minimum of one episode of being intolerant, or unresponsive to the treatment, see Appendices 2-4.\n* The investigator deems the patient is either contraindicated or inappropriate for the treatment. Inappropriateness could be due to anticipated changes in patient status (i.e., such as worsening of comorbidities or use of concomitant medication), see Appendices 2-4.\n* Patients must be willing and capable of using an electronic device (e.g., cellphone) and must have access to a cellphone to be able to complete surveys.\n\nExclusion Criteria:\n\n* Patients with scleroderma, osteoporosis, active or recurrent bacterial, fungal or viral infections, ocular herpes simplex, recent surgery (within 2 weeks prior to randomization or have an unhealed operation wound(s)), history of or the presence of a peptic ulcer, uncontrolled congestive heart failure, uncontrolled hypertension, uncontrolled diabetes type 1 or 2, or sensitivity to proteins derived from porcine sources.\n* Patients with primary adrenocortical insufficiency or adrenocortical hyperfunction.\n* Rheumatoid arthritis, evidence or suspicion of infectious\u002Fseptic arthritis, or other acute inflammatory arthritis.\n* Polyarticular gouty arthritis involving more than 4 joints.\n* Participation in another concurrent investigational study within 30 days of randomization or has taken an investigational drug within five times the half-life of that investigational drug has passed.\n* Previous inclusion in this study.\n* Presence of severe renal function impairment: estimated creatinine clearance \\\u003C30 mL\u002Fmin\u002F1.73m2 (CKD stages 4 and 5).\n* Uncontrolled clinically significant hematologic, CNS, hepatic, pulmonary, gastrointestinal, metabolic, or endocrine disease as deemed by the investigator.\n* Presence of any medical or psychological condition or laboratory result that might create risk to the patients (or interfere with the patient's ability to comply with the protocol requirements, or to complete the study) in the opinion of the investigator.\n* Prior or current treatment with any ACTH product.\n* Pregnant or nursing (lactating) women. Women of childbearing age are required to be using an acceptable method of contraception.\n* Patients taking urate-lowering therapy had to be on a stable dose and regimen for ≥2 weeks before entering the study and remain on a stable dosage and regimen for at least 1 week after Purified Cortrophin® Gel.\n* Use of specified pain relief medications or biologics (including glucocorticoids, narcotics, paracetamol\u002Facetaminophen, NSAIDs, colchicine, IL-blockers and tumor necrosis factor \\[TNF\\] inhibitors) within specified periods (see Appendix 5) prior to randomization.\n\n  * Vaccination within 30 days prior to study enrollment and during the study period.","18 Years","90 Years",{"count":63,"type":21},150,[24],"This is a randomized, multicenter, double-blind, single administration study to investigate the efficacy and safety of 2 dosing regimens of Purified Cortrophin® Gel in the treatment of an acute gouty arthritis flare.\n\nThe study consists of three periods: an optional pre-screening period, a double-blind treatment period, and a 7-day follow-up period.\n\nThe treatment period is double-blind, and the patients will be randomized to treatment with 40 U Purified Cortrophin® Gel or 80 U Purified Cortrophin® Gel in a 1:1 ratio. Purified Cortrophin® Gel will be administered once (either subcutaneously or intramuscularly) on the first visit (Day 0; Visit 1) and surveyed after 24 hours (Day 1), 48 hours (Day 2), and 72 hours (Day 3; Visit 2) as well as on Day 7.",[28,67,68],"Gout Flare","Gout","RECRUITING","2026-01-15",{"date":47,"type":45},{"date":73,"type":45},"2025-12-20",{"date":75,"type":21},"2027-08-31",{"name":77,"class":52},"Massachusetts General Hospital",1,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":18,"minAge":60,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":22,"phases":88,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":4},"100616959","an-exploratory-clinical-study-on-the-protective-effect-of-cycling-on-the-ankle-joint-in-gout-100616959","NCT07312396","An Exploratory Clinical Study on the Protective Effect of Cycling on the Ankle Joint in Gout","Inclusion Criteria:\n\n* meets the diagnostic criteria for gout of the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) in 2015\n* There have been two histories of gout attacks on either side of the ankle joint in the past six months\n* Ultrasound examination within the past 6 months indicated that either ankle joint had characteristic ultrasound manifestations (double-track sign, and\u002For hyperechoic aggregates, and\u002For tophi, and\u002For bone destruction)\n* Those who have had an interval of at least 4 weeks since the most recent acute gout attack\n* If the patient is undergoing uric acid-lowering drug treatment, the drug dosage must remain stable for more than 4 weeks. During the study period, the uric acid-lowering drug regimen or dosage will not be adjusted\n* For women who have the potential to become pregnant, a pregnancy test must be negative, they must not be in the lactation period, and it must be confirmed that they are receiving contraception approved by the researcher and agree to maintain this contraceptive measure throughout the study process\n* Those who were informed of this study and signed the informed consent form\n\nExclusion Criteria:\n\n* Those who have received intra-articular injections of corticosteroids during an attack within the past three months; Those who have taken colchicine, NSAIDs, glucocorticoids in the past two weeks, or those who need to maintain anti-inflammatory drug treatment for a long time during the follow-up period\n* Joint trauma or other types of arthritis\n* There is a history of joint prosthesis or joint surgery\n* Those who have had acute gout attacks within 4 weeks\n* Patients with secondary gout caused by kidney diseases, blood disorders, or taking certain medications, radiotherapy and chemotherapy for tumors, etc\n* Those with severe and unstable cardiovascular and cerebrovascular diseases (such as unstable angina pectoris, coronary angiogenesis, cerebral angiogenesis, transient ischemic attack, congestive heart failure, etc.) and other diseases that researchers have determined to be acute and difficult to control","60 Years",{"count":87,"type":21},90,[89],"NA","This study divided the enrolled gout patients into a jogging group and a cycling group to investigate 1）the effectiveness of cycling intervention in reducing the recurrence risk of gouty ankle arthritis compared with jogging. 2) To clarify the influence of different exercise patterns on the ultrasonic manifestations of gouty ankle arthritis; 3) Clarify the impact of different exercise methods on the blood uric acid levels of gout patients;",[28,92,93],"Cycling","Physical Activity","2025-12-16",{"date":96,"type":45},"2025-12-31",{"date":98,"type":21},"2026-01-01",{"date":100,"type":21},"2027-12-30",{"name":102,"class":52},"Zhu Xiaoxia",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":18,"minAge":60,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":22,"phases":113,"briefSummary":114,"conditions":115,"keywords":120,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":131},"100590724","nurse-led-telehealth-for-gout-100590724","NCT06971146","Nurse-Led Telehealth for Gout","Health Literacy-Based, Nurse-Led Telehealth Support for Gout Self-Management: the Danish Randomized GOUTCONNECT Trial","GoutConnect","Inclusion Criteria:\n\n* ≥18 years old\n* Fulfills ACR\u002FEULAR 2015 Gout Classification Criteria\n* Estimated Glomerular Filtration Rate (e-GFR) \\>30 ml\u002Fmin\n* Prescribed Allopurinol or Adenuric, and achieved two consecutive serum urate levels of two consecutive serum urate levels of ≤0.30 mmol\u002Fl for patients with tophi and ≤0.36 mmol\u002FL for patients without tophi\n* Have sufficient Danish reading and writing skills to understand information and complete questionnaires.\n\nExclusion Criteria:\n\n• Cognitively impaired, unable to understand or provide informed consent.",{"count":112,"type":21},200,[89],"The aim of this clinical trial is to evaluate whether nurse-led telehealth support helps individuals with gout better manage their condition and adhere to urate-lowering medication after discharge from a rheumatology clinic.\n\nEligible patients will be recruited from five rheumatology departments in the Central Denmark Region after achieving two consecutive target serum urate levels-below 0.36 mmol\u002FL, or below 0.30 mmol\u002FL for patients with tophi.\n\nParticipants will be adults with gout who meet specific medical criteria, are taking medications such as allopurinol or Adenuric, and are able to read and write Danish.\n\nParticipants will be randomly assigned to one of two groups:\n\n* Intervention group: nurse-led telehealth support.\n* Control group: usual care with follow-up by their general practitioner.\n\nThe primary goal is to support patients in maintaining healthy uric acid levels after 52 weeks.\n\nParticipants in the nurse-led group have the option to choose from four support options:\n\nI1: App-Based Support - an app provides information and reminders. I2: Letter Reminders - messages are sent via digital or postal mail. I3: Text Reminders - SMS messages are sent every three months. I4: Phone Support - nurses call three times a year to check in.",[116,28,27,117,118,119],"Health Literacy","Telehealth","Digital Health","Adherence",[121],"self-managment","2025-09-17",{"date":124,"type":45},"2025-09-18",{"date":126,"type":21},"2025-10-01",{"date":128,"type":21},"2027-08-01",{"name":130,"class":52},"University of Aarhus",5,{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":138,"eligibilityCriteria":139,"healthyVolunteers":17,"sex":18,"minAge":60,"maxAge":4,"enrollmentInfo":140,"targetDuration":4,"studyType":142,"phases":4,"briefSummary":143,"conditions":144,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":78},"100604475","clinical-assessment-for-rheumatologic-disease---research-and-advancement-in-safety-and-efficacy-100604475","NCT07150000","Clinical Assessment for Rheumatologic Disease - Research and Advancement in Safety and Efficacy","CARe RAiSE Study - Clinical Assessment for Rheumatologic Disease - Research and Advancement in Safety and Efficacy","CARe RAiSE","Inclusion Criteria:\n\n* Participants aged ≥ 18 years\n* Signed written informed consent to participate voluntarily in the study.\n* Confirmed diagnosis (by the treating physician) of one of the following autoimmune or autoinflammatory rheumatic diseases:\n* Rheumatoid arthritis (RA)\n* Psoriatic arthritis (PsA)\n* Axial spondyloarthritis (axSpA)\n* Giant cell arteritis (GCA)\n* Connective tissue diseases, including:\n\n  1. Systemic lupus erythematosus (SLE)\n  2. Systemic sclerosis (SSc)\n  3. Mixed connective tissue disease (MCTD)\n  4. Idiopathic inflammatory myopathies (IIM)\n* ANCA-associated vasculitides (AAV), including:\n\n  1. Microscopic polyangiitis (MPA)\n  2. Granulomatosis with polyangiitis (GPA)\n  3. Eosinophilic granulomatosis with polyangiitis (EGPA)\n* Autoinflammatory diseases, including\n\n  1. Familial Mediterranean fever (FMF)\n  2. Cryopyrin-associated periodic syndromes (CAPS)\n  3. TNF receptor-associated periodic syndrome (TRAPS)\n  4. Adult-onset Still's disease (AOSD)\n\n     Exclusion Criteria:\n* Refusal to participate in the study or inability to provide informed consent.\n\nInclusion Criteria - Healthy Control Group:\n\n* Participants aged ≥ 18 years (capable of providing informed consent).\n* Signed written informed consent to participate voluntarily in the study.\n\nExclusion Criteria - Healthy Control Group:\n\n\\- Presence of a known or active rheumatologic disease.",{"count":141,"type":21},120,"OBSERVATIONAL","The CARe RAiSE project represents a pioneering translational initiative aimed at advancing precision medicine in the treatment of autoimmune rheumatic diseases. The primary objective is the development and implementation of an innovative cell-based ex vivo assay that enables individualized prediction of therapeutic response to disease-modifying antirheumatic drugs (DMARDs). By identifying the most effective treatment option for each patient, this approach seeks to enhance therapeutic efficacy, reduce time to clinical response, and minimize healthcare costs.\n\nDespite the availability of numerous DMARDs, clinical decision-making remains largely empirical due to considerable interindividual variability in treatment response. This frequently results in a prolonged trial-and-error process, placing a significant burden on patients and the healthcare system. CARe RAiSE aims to overcome this limitation by providing a functional diagnostic tool that can predict a patient's immunological response to specific DMARDs prior to treatment initiation.\n\nThe assay is based on peripheral blood mononuclear cells (PBMCs) obtained from individual patients, enabling a physiologically relevant assessment of immune responsiveness to targeted therapies. Combining high-content imaging with homogeneous well-based cytokine and inflammasome activity assays, the platform allows for a detailed single-cell analysis of inflammatory pathways. These data are used to generate predictive signatures of treatment response, thereby facilitating a mechanistically informed and personalized therapeutic strategy.\n\nThrough this approach, CARe RAiSE introduces a scientifically grounded, efficient, and patient-specific method for DMARD selection, with the potential to substantially improve patient outcomes and reduce the socioeconomic impact of autoimmune rheumatic diseases.",[145,146,147,148,149,150,151,152,153,154,155,156,28],"Rheumatic Diseases","Rheumatoid Arthritis (RA)","Giant Cell Arteritis (GCA)","Psoriatic Arthritis (PsA)","Axial Spondylarthritis (axSpA)","Polymyalgia Rheumatica (PMR)","ANCA Associated Vasculitis (AAV)","Connective Tissue Disease (CTD)","Systemic Sclerosis (SSc)","Systemic Lupus Erthematosus (SLE)","Idiopathic Inflammatory Myopathy (IIM)","Autoinflammatory Disease","2025-08-24",{"date":159,"type":45},"2025-09-02",{"date":161,"type":45},"2025-04-01",{"date":163,"type":21},"2028-12",{"name":165,"class":52},"University of Bonn",{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":4,"eligibilityCriteria":172,"healthyVolunteers":11,"sex":18,"minAge":60,"maxAge":4,"enrollmentInfo":173,"targetDuration":4,"studyType":22,"phases":175,"briefSummary":177,"conditions":178,"keywords":180,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":78},"100582468","phase-3-efficacy-anda-safety-of-etoricoxib-with-betamethasone-for-the-treatment-of-acute-gout-arthritis-100582468","NCT06863701","Efficacy Anda Safety of Etoricoxib With Betamethasone for the Treatment of Acute Gout Arthritis","Efficacy and Safety Study for the Combination of Etoricoxib \u002F Betamethasone Compared to Etoricoxib for the Treatment of Patients Diagnosed With Acute Gout Arthritis","Inclusion Criteria:\n\n* Willing to participate in the study and provide written informed consent.\n* Women of childbearing potential and sexually active must use an acceptable contraceptive method (barrier and\u002For hormonal) as determined by the investigator.\n* History of hyperuricemia diagnosis (uric acid \\> 7 mg\u002FdL) reported in medical history or patient interview.\n* Clinical diagnosis of acute gouty arthritis with a score of at least 4 based on the following criteria: Male (2 points), history of a similar episode (2 points), symptom onset within the last 24 hours (0.5 points), joint redness (1 point), involvement of the first metatarsophalangeal joint (2.5 points), and hypertension or at least one cardiovascular disease (1.5 points).\n* Acute episode characterized by severe pain, inflammation, edema, and erythema in the affected joint (≤ 48 hours before study inclusion).\n* In the opinion of the Principal Investigator or treating physician, the patient is eligible for treatment with the investigational product and may benefit clinically\n\nExclusion Criteria:\n\n* Patients participating in another clinical study involving an investigational treatment or participation in one within the two weeks prior to study initiation.\n* Patients whose participation in the study may be influenced (e.g., employment relationship with the research center or sponsor, vulnerable populations, etc.).\n* In the investigator's judgment, any condition that affects prognosis and prevents outpatient management, which must be assessed by the principal investigator to determine the patient's eligibility.\n* History of severe, progressive, or unstable advanced disease of any kind that may interfere with efficacy and safety evaluations or put the patient at risk.\n* Pregnant or breastfeeding patients.\n* The study medication is contraindicated for medical reasons.\n* History of intolerance or allergic reaction to NSAIDs (nonsteroidal anti-inflammatory drugs), paracetamol, or known hypersensitivity to any component of the formulation.\n* Significant history of gastrointestinal disorders (e.g., gastric ulcer, Crohn's disease, ulcerative colitis, gastrointestinal bleeding, etc.).\n* History of congestive heart failure (NYHA classification II-IV), established ischemic heart disease, peripheral arterial disease, and\u002For cerebrovascular disease (including patients who have recently undergone coronary revascularization or angioplasty).\n* Treatment with systemic corticosteroids for the management of acute gouty arthritis within two weeks before study initiation.\n* Treatment with NSAIDs within 48 hours prior to study initiation, except for aspirin at cardioprotective doses.\n* History of treatment failure with selective COX-2 inhibitors, as reported in medical history or patient interview.\n* Presence of acute polyarticular gout affecting more than four joints.\n* History of alcohol or drug abuse within the past year.\n* Clinical suspicion of joint infection or another joint disease different from acute gouty arthritis.\n* History of chronic liver failure (Child-Pugh A, B, and\u002For C), as reported in medical history or patient interview.\n* History of chronic renal failure (glomerular filtration rate \\\u003C30 ml\u002Fmin\u002F1.73 m²), as reported in medical history or patient interview.\n* Significant history of known coagulation disorders (e.g., Von Willebrand disease, hemophilia, vitamin K deficiency, etc.) or use of anticoagulants, as reported in medical history or patient interview.\n* Oncology patients (except for basal cell skin cancer) or patients with severe diseases that, in the investigator's opinion, have a severe prognosis or a life expectancy of less than one year, as well as patients with mental illnesses.\n* Patients with symptoms suggestive of active COVID-19 infection (e.g., fever, cough, shortness of breath) and\u002For contact within the last 14 days with a suspected or confirmed COVID-19 case.",{"count":174,"type":21},72,[176],"PHASE3","Phase III longitudinal, multicenter, randomized, double-blind clinical trial. The aim of this study is to evaluate the efficacy and safety of the Fixed-Dose Combination of Etoricoxib\u002FBetamethasone Versus Etoricoxib in Patients With Acute Gouty Arthritis",[28,179],"Gout Attack",[28,179,181,182],"Etoricoxib","Betamethasone",{"date":184,"type":45},"2025-04-03",{"date":186,"type":45},"2025-01-27",{"date":188,"type":21},"2027-01-31",{"name":190,"class":191},"Laboratorios Silanes S.A. de C.V.","INDUSTRY"]